MS biologics comparison
NeurologyCompare disease-modifying therapies (DMTs) for multiple sclerosis. Options range from platform therapies to high-efficacy B-cell depleting agents. Choice depends on disease activity, safety profile, route preference, and insurance coverage.
Select any two to compare side by side
All products in this comparison
| Product | Manufacturer | Route | Frequency | Key difference |
|---|---|---|---|---|
| Ocrevus | Genentech/Roche | IV infusion | Every 6 months | Only FDA-approved treatment for primary progressive MS; high-efficacy anti-CD20 |
| Kesimpta | Novartis | SC injection (at home) | Monthly | Self-administered anti-CD20; no infusion center required |
| Briumvi | TG Therapeutics | IV infusion | Every 6 months | Anti-CD20; potentially lower cost than Ocrevus |
| Tysabri | Biogen | IV infusion | Every 4 weeks | High efficacy; requires JCV monitoring (PML risk); REMS program |
| Gilenya | Novartis | Oral (capsule) | Daily | First oral MS therapy; S1P receptor modulator; requires first-dose monitoring |
| Tecfidera | Biogen | Oral (capsule) | Twice daily | Oral fumarate; generics now available (dimethyl fumarate) |
| Vumerity | Biogen | Oral (capsule) | Twice daily | Next-gen fumarate; potentially fewer GI side effects than Tecfidera |
| Mavenclad | Merck KGaA | Oral (tablet) | 2 treatment courses over 2 years, then off therapy | Short-course therapy with long-lasting effect; no daily medication |
| Rebif | Merck KGaA | SC injection | 3 times weekly | Interferon beta-1a; platform therapy; long track record |
Related guides
Denied one of these medications?
Ellen can decode your denial letter, identify why you were denied, and generate a personalized appeal, free for patients.